

Angle New Parsortix data

A boost for prostate cancer indication

Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle's Parsortix system for use in prostate cancer applications including an unexpected fundamental discovery that might ignite interest as a new research area in cancer metastasis. The study analysed blood samples from 81 prostate cancer patients and showed that Parsortix captured so-called EMTing cancer cells, those circulating tumour cells (CTCs) that are undergoing epithelial to mesenchymal transition. EMTing cells were correlated with whether the cancer became metastatic. Namely, the researchers found that EMTing cells combined with the gold standard PSA test had 92% accuracy in predicting metastasis, significantly outperforming PSA alone. The ability to capture EMTing and EMTed cells is what differentiates Parsortix from many other liquid biopsy systems. We are updating our estimates.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
04/13	0.97	(0.65)	(1.61)	0.0	N/A	N/A
04/14	0.00	(2.04)	(2.39)	0.0	N/A	N/A
04/15	0.00	(3.55)	(7.50)	0.0	N/A	N/A
04/16	0.36	(5.03)	(7.97)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, share-based payments

The novel finding was the first ever proof that megakaryocytes are present in the blood of prostate cancer patients, albeit very rare. Usually these cells are found in bone marrow and produce platelets for blood clotting. In contrast with EMTed cells (cancer cells that have completed the EMT process), megakaryocytes were found to be associated with better outcomes for prostate cancer patients. The team developed a combined scoring system based on EMTed cells and megakaryocytes harvested by Parsortix. Using data from a subset of 40 patients followed over a 20-month period, the scoring system was able to identify patients who were 10 times more likely to die from the disease in the short term.

BCI researchers believe there is potential that megakaryocytes are similarly linked to improved patient survival in other cancer types as well. For Angle we see several implications in the short and longer term. In the short term we see the news as a boost for prostate cancer application, which may prompt us to revise our success probability to reach the market in our model (see our March 2016 update note). Given that the discovery of megakaryocytes in the blood stream is fundamental, it may trigger other research groups to start investigating this area. So far, only Angle's Parsortix has been shown to have the ability to capture these cells, which may translate into higher Parsortix sales for research use. In the long run, the discovery could lead to higher interest in using liquid biopsy tools for diagnosing cancer patients.

Pharma & biotech

16 June 2017

Price	72.25p
Market cap	£54m

Market cap £54m

Estimated net cash (£m) at end-April 2017 5.5

Shares in issue 74.8


Free float 90%

Code AGL

Primary exchange AIM

Secondary exchange OTC QX

Share price performance



Business description

Angle is a specialist diagnostics company. The proprietary Parsortix cell separation platform can be used for detecting and harvesting very rare circulating tumour cells from blood samples. The resulting liquid biopsy enables the analysis of these cells for precision cancer care. Angle has identified ovarian cancer, prostate cancer and metastatic breast cancer as the most likely indications.

Analyst

Jonas Peciulis +44 (0)20 3077 5728

healthcare@edisongroup.com

Edison profile page

Angle is a research client of Edison Investment Research Limited



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholes ale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Angle and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from public) available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research and and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation of effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This documen